他汀类药物的使用与台湾缺血性心脏病患者前列腺癌风险的关系。
Statin Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan.
机构信息
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
出版信息
Clin Pharmacol Ther. 2019 Aug;106(2):458-466. doi: 10.1002/cpt.1408. Epub 2019 May 14.
Patients with ischemic heart disease (IHD) are more likely to be diagnosed with prostate cancer. Statins, which are widely used in such patients, are shown to modify the risk of prostate cancer. To clarify the association between statin use and the risk of prostate cancer among patients with higher risk of developing prostate cancer in Taiwan, a cohort of 26,628 men with IHD and aged between 55 and 100 were acquired from the National Health Insurance Research Database and followed over a period of 8 years. The risk of prostate cancer was calculated by time-dependent Cox regression model. Statin use was associated with significantly lower risk of both total and advanced prostate cancer (adjusted hazard ratio (HR): 0.719, 95% confidence interval (CI): 0.570-0.908; adjusted HR: 0.718, 95% CI: 0.530-0.972 respectively). In Taiwan IHD population, the reduction in risk of prostate cancer was observed in statin users as compared with nonusers.
患有缺血性心脏病 (IHD) 的患者更有可能被诊断出患有前列腺癌。广泛用于此类患者的他汀类药物被证明可以改变前列腺癌的风险。为了阐明在台湾，使用他汀类药物与患有更高前列腺癌风险的患者的前列腺癌风险之间的关联，从国家健康保险研究数据库中获得了一组年龄在 55 至 100 岁之间的 26628 名患有 IHD 的男性，并对其进行了为期 8 年的随访。通过时间依赖性 Cox 回归模型计算前列腺癌的风险。他汀类药物的使用与总前列腺癌和晚期前列腺癌的风险显著降低相关（调整后的危害比（HR）：0.719，95%置信区间（CI）：0.570-0.908；调整后的 HR：0.718，95% CI：0.530-0.972）。在台湾 IHD 人群中，与非使用者相比，使用他汀类药物的患者前列腺癌风险降低。
Zotero 插件